Cargando…

Effectiveness and safety of recombinant zoster vaccine: A review of real-world evidence

The recombinant zoster vaccine (RZV) was licensed in the US for prevention of herpes zoster (HZ) in 2017. We conducted a literature search (January 1, 2017–August 1, 2023) using PubMed, Embase, and Scopus to consolidate the real-world evidence related to RZV. Overall, RZV effectiveness against HZ wa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parikh, Raunak, Singer, David, Chmielewski-Yee, Elizabeth, Dessart, Christophe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653743/ https://www.ncbi.nlm.nih.gov/pubmed/37967254 http://dx.doi.org/10.1080/21645515.2023.2263979

Ejemplares similares

1156. Real-World Effectiveness of Recombinant Zoster Vaccine in Chinese Adults Aged ≥50 Years in the US
por: Florea, Ana, et al.
Publicado: (2023)

2776. Post-marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Review of Spontaneous Reports Since Introduction
por: Tavares-Da-Silva, Fernanda, et al.
Publicado: (2019)

Recombinant Zoster Vaccine Is Efficacious and Safe in Frail Individuals
por: Curran, Desmond, et al.
Publicado: (2020)

5. How Does Frailty Impact the Efficacy, Reactogenicity, Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine? A Secondary Analysis of the ZOE-50 and ZOE-70 Studies
por: Andrew, Melissa K, et al.
Publicado: (2020)

Real-World Effectiveness and Safety of a Live-Attenuated Herpes Zoster Vaccine: A Comprehensive Review
por: Ansaldi, Filippo, et al.
Publicado: (2016)

2480. Real-World Effectiveness of the Live Zoster Vaccine in Preventing Herpes Zoster: A Systematic Review
por: Saddier, Patricia, et al.
Publicado: (2018)

Efficacy and safety of the recombinant zoster vaccine: A systematic review and meta-analysis
por: Zeevaert, Renate, et al.
Publicado: (2023)

A Broad Safety Assessment of the Recombinant Herpes Zoster Vaccine
por: Yih, W Katherine, et al.
Publicado: (2022)

Preventing Varicella-Zoster: Advances With the Recombinant Zoster Vaccine
por: Ilyas, Sahrish, et al.
Publicado: (2020)

Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model
por: Patterson, Brandon J, et al.
Publicado: (2020)

Herpes Zoster Following Recombinant Zoster Vaccine With or Without Concomitant Vaccination
por: Bruxvoort, Katia J, et al.
Publicado: (2022)

Herpes zoster in outpatient departments of healthcare centers in India: a review of literature
por: Patki, Anil, et al.
Publicado: (2021)

Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology
por: Tavares-Da-Silva, Fernanda, et al.
Publicado: (2020)

An update on national recommendations for the use of the adjuvanted recombinant zoster vaccine: Romy Weller
por: Parikh, R, et al.
Publicado: (2022)

Can COVID-19 Increase the Risk of Herpes Zoster? A Narrative Review
por: Diez-Domingo, Javier, et al.
Publicado: (2021)

Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review
por: Giannelos, Nikolaos, et al.
Publicado: (2023)

Correction to: Can COVID-19 Increase the Risk of Herpes Zoster? A Narrative Review
por: Diez-Domingo, Javier, et al.
Publicado: (2021)

The Real-World Study of Immunogenicity and Safety of the Adjuvant Recombinant Vaccine against Varicella Zoster Virus in Patients with Immune-Mediated Inflammatory Diseases Treated with Janus Kinase Inhibitors
por: Esteban-Vazquez, Ana, et al.
Publicado: (2023)

20. Cost-Effectiveness of Recombinant Zoster Vaccine for Vaccinating Immunocompromised Adults Against Herpes Zoster in the United States
por: Curran, Desmond, et al.
Publicado: (2021)

Healthy ageing: Herpes zoster infection and the role of the adjuvanted recombinant zoster vaccine
por: Curran, D, et al.
Publicado: (2022)

Uveitis reactivation following recombinant zoster vaccination
por: Richards, Paige J., et al.
Publicado: (2021)

Real‐world evidence from over one million COVID‐19 vaccinations is consistent with reactivation of the varicella‐zoster virus
por: Hertel, M., et al.
Publicado: (2022)

Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials
por: López-Fauqued, Marta, et al.
Publicado: (2021)

Early examination of real-world uptake and second-dose completion of recombinant zoster vaccine in the United States from October 2017 to September 2019
por: Patterson, Brandon J., et al.
Publicado: (2021)

Estimated Public Health Impact of the Recombinant Zoster Vaccine
por: Patterson, Brandon J., et al.
Publicado: (2021)

4. Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Adults
por: Dagnew, Alemnew F, et al.
Publicado: (2020)

Active Postlicensure Safety Surveillance for Recombinant Zoster Vaccine Using Electronic Health Record Data
por: Nelson, Jennifer C, et al.
Publicado: (2022)

Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer
por: Curran, Desmond, et al.
Publicado: (2023)

Herpes Zoster and Immunogenicity and Safety of Zoster Vaccines in Transplant Patients: A Narrative Review of the Literature
por: Wang, Lei, et al.
Publicado: (2018)

Recombinant zoster vaccine (Shingrix(®)): a new option for the prevention of herpes zoster and postherpetic neuralgia
por: Singh, Grisuna, et al.
Publicado: (2020)

Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies
por: Mwakingwe-Omari, Agnes, et al.
Publicado: (2023)

The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine
por: Dagnew, Alemnew F, et al.
Publicado: (2020)

Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination
por: Strezova, Ana, et al.
Publicado: (2022)

Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines
por: Marra, Yasmin, et al.
Publicado: (2022)

Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) — United States, October 2017–June 2018
por: Hesse, Elisabeth M., et al.
Publicado: (2019)

36. Safety and Reactogenicity of the Adjuvanted Recombinant Zoster Vaccine after Allogeneic Hematopoietic Stem Cell Transplantation
por: Baumrin, Emily, et al.
Publicado: (2020)

37. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine (RZV) in Immunocompromised Populations: an Overview of 6 Trials
por: Fauqued, Marta Lopez, et al.
Publicado: (2020)

Safety and reactogenicity of the adjuvanted recombinant zoster vaccine: experience from clinical trials and post-marketing surveillance
por: Fiore, Joseph, et al.
Publicado: (2021)

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial
por: Vink, Peter, et al.
Publicado: (2019)

Multidisciplinary model for administration of recombinant Zoster vaccine in fragile patients
por: Martinelli, S, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_n46t0if5bam4b0oa5r465hpfsf